✨ Free AI Report
Kiora Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Kiora Pharmaceuticals, Inc.
Company Research

Kiora Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Kiora Pharmaceuticals, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Well-positioned clinical-stage ophthalmology specialist with novel molecular photoswitches, strong partnerships, and adequate runway, but success hinges entirely on Phase 2 trial outcomes. Kiora demonstrates solid scientific progress with two actively enrolling Phase 2 trials and meaningful partnership validation from established pharma (Senju, Théa). The company maintains runway into late.

What is Kiora Pharmaceuticals, Inc.'s industry? Kiora Pharmaceuticals, Inc. (kiorapharma.com) operates in Pharmaceuticals. AskCyborg classifies Kiora Pharmaceuticals, Inc. under Pharmaceuticals in its company registry.

Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing advanced treatments for retinal disease. The company targets critical pathways underlying eye disease with innovative small molecules to p...

6/ 10Solid

Cyborg Score thesis

Well-positioned clinical-stage ophthalmology specialist with novel molecular photoswitches, strong partnerships, and adequate...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Kiora Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Kiora Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Kiora Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Kiora Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Kiora Pharmaceuticals, Inc. Overview

Pro stress-test →

Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing advanced treatments for retinal disease. The company targets critical pathways underlying eye disease with innovative small molecules to preserve, slow, or restore vision loss. The company is advancing two Phase 2 clinical trials with potential to address significant unmet needs in inherited and inflammatory retinal conditions.

Strategic Profile

Pro stress-test →

The lead product KIO-301 is a potential vision-restoring small molecule in Phase 2 clinical trials for retinitis pigmentosa, choroideremia, and Stargardt disease. The company entered into an option agreement with Senju Pharmaceutical for development and commercialization in Asia with a potential deal value of up to $110 million plus royalties (August 2025). Kiora has a strategic development and commercialization agreement with Théa Open Innovation for KIO-301.

Competitive Landscape

Pro stress-test →

Kiora was incorporated in 1998 and was formerly known as Eyegate Pharmaceuticals before rebranding in November 2021. The company operates in a specialized niche—inherited and inflammatory retinal diseases—with limited direct competition for molecular photoswitches. Major ophthalmic competitors (Novartis, Allergan, Bausch Health) operate in broader eye care; Kiora's photoswitch approach is novel but clinical-stage success is essential. Partnership validation from Senju and Théa signals confidence in scientific approach.

Industry Context

Kiora Pharmaceuticals, Inc. operates in Pharmaceuticals.

Key facts

Founded: 1998 · Headquarters: Encinitas, California, US

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Kiora Pharmaceuticals, Inc..

  • Lead program KIO-301 targets three major inherited retinal diseases with unmet need; ABACUS-2 trial actively enrolling with validated functional vision assessment endpoint
  • Secondary program KIO-104 addresses retinal inflammation (KLARITY trial) with patent protection extended to 2043, reducing competitive risk
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Reported Q3 2025 net income of $27k vs. Q3 2024 loss of $3.4M; continued recruitment in both KLARITY and ABACUS-2 Phase 2 trials
  • October 2025Joined Global Genes' RARE-X Vision Consortium to accelerate rare ocular disorder research and clinical trial design
  • +2 moreTrack every material event for Kiora Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Kiora Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LuxturnaGene therapy for inherited retinal dystrophy→BeovuAnti-VEGF for wet age-related macular degeneration→RestasisImmunosuppressant for dry eye disease→XiidraLymphocyte function antigen antagonist for dry eye→

Compare Kiora Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Kiora Pharmaceuticals, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Kiora Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Kiora Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Kiora Pharmaceuticals, Inc. do this quarter?”
“Is Kiora Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Kiora Pharmaceuticals, Inc. do?+
Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing advanced treatments for retinal disease. The company targets critical pathways underlying eye disease with innovative small molecules to p...
What is Kiora Pharmaceuticals, Inc.'s Cyborg Score?+
Kiora Pharmaceuticals, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Kiora Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Luxturna, Beovu, Restasis, Xiidra. The full competitive landscape is in the AskCyborg report.
How can I get the full Kiora Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Kiora Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Kiora Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.